Vivus: Ready To Gain From Qnexa
by | Posted 4.10.2012 | Post Comment (No Comments)

Biopharmaceutical stocks have always been a gamble that can have dramatic increases or dramatic decreases. VIVUS (VVUS) is set to have one of these huge changes over the next couple of weeks from its latest drug, Qnexa. This obesity treatment drug has been making the headlines since 2010, when it was rejected by the FDA due to too little amounts of testing.

Read the rest of this post @ DividendKings